Contribution of the interleukin-6/STAT-3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1250-1260

  Kondo, Masahiro ^a   Yamaoka, Kunihiro ^a   Sakata, Kei ^a   Sonomoto, Koshiro ^a   Lin, Lin ^a   Nakano, Kazuhisa ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; AGGRECAN; COLLAGEN TYPE 10; COLLAGEN TYPE 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NESTIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA3; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; MESSENGER RNA; SOX9 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CARTILAGE CELL; CARTILAGE MATRIX; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; CULTURE MEDIUM; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL CULTURE; SUPERNATANT; AGED; ARTICULAR CARTILAGE; CARTILAGE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGGRECANS; CARTILAGE; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; CHONDROCYTES; CHONDROGENESIS; COLLAGEN TYPE II; COLLAGEN TYPE X; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84928633255     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39036     Document Type: Article

References (40)

1. Goldring MB, Marcu KB., Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009; 11: 224.
2. Alsalameh S, Amin R, Gemba T, Lotz M., Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis Rheum 2004; 50: 1522-32.
3. Dowthwaite GP, Bishop JC, Redman SN, Khan IM, Rooney P, Evans DJR, et al. The surface of articular cartilage contains a progenitor cell population. J Cell Sci 2004; 117: 889-97.
4. Pretzel D, Linss S, Rochler S, Endres M, Kaps C, Alsalameh S, et al. Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage. Arthritis Res Ther 2011; 13: R64.
5. Grogan SP, Miyaki S, Asahara H, D'Lima DD, Lotz MK., Mesenchymal progenitor cell markers in human articular cartilage: normal distribution and changes in osteoarthritis. Arthritis Res Ther 2009; 11: R85.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
7. Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, et al. Mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 2012; 1: 51-8.
8. Oshita K, Yamaoka K, Udagawa N, Fukuyo S, Sonomoto K, Maeshima K, et al. Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. Arthritis Rheum 2011; 63: 1658-67.
9. Caplan AI, Dennis JE., Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-84.
10. Chen L, Tredget EE, Wu PY, Wu Y., Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3: e1886.
11. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013; 72: 482-92.
12. Naka T, Nishimoto N, Kishimoto T., The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4 Suppl 3: S233-42.
13. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-20.
14. Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS., Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem 2009; 108: 577-88.
15. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2-Δ Δ C t Method. Methods 2001; 25: 4028.
16. Aggarwal S, Pittenger MF., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
17. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B., The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002; 16: 2813-28.
18. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B., Sox9 is required for cartilage formation. Nat Genet 1999; 22: 85-9.
19. Huang W, Zhou X, Lefebvre V, de Crombrugghe B., Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate aCol2a1 chondrocyte-specific enhancer. Mol Cell Biol 2000; 20: 4149-58.
20. Huang W, Chung UI, Kronenberg HM, de Crombrugghe B., The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc Natl Acad Sci 2001; 98: 160-5.
21. Kondo M, Yamaoka K, Sonomoto K, Fukuyo S, Oshita K, Okada Y, et al. IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells. PLoS One 2013; 8: e79463.
22. Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, et al. Nestin expression: a property of multi-lineage progenitor cells? Cell Mol Life Sci 2004; 61: 2510-22.
23. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-34.
24. Tondreau T, Lagneaux L, Dejeneffe M, Massy M, Mortier C, Delforge A, et al. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004; 72: 319-26.
25. Sonomoto K, Yamaoka K, Oshita K, Fukuyo S, Zhang X, Nakano K, et al. Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. Arthritis Rheum 2012; 64: 3355-63.
26. Okada A, Yamasaki S, Koga T, Kawashiri SY, Tamai M, Origuchi T, et al. Adipogenesis of the mesenchymal stromal cells and bone oedema in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: 332-7.
27. Schaefer TS, Sanders LK, Park OK, Nathans D., Functional differences between Stat3α and Stat3β. Mol Cell Biol 1997; 17: 5307-16.
28. Ozbey O, Sahin Z, Acar N, Ustunel I., Distribution of CD105 and CD166 positive cells in the proximal epiphysis of developing rat humerus. Histol Histopathol 2010; 25: 1437-45.
29. Beekhuizen M, Bastiaansen-Jenniskens YM, Koevoet W, Saris DB, Dhert WJ, Creemers LB, et al. Osteoarthritic synovial tissue inhibition of proteoglycan production in human osteoarthritic knee cartilage: establishment and characterization of a long-term cartilage-synovium coculture. Arthritis Rheum 2011; 63: 1918-27.
30. De Hooge AS, van de Loo FA, Bennink MB, Arntz OJ, de Hooge P, van den Berg WB., Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthritis Cartilage 2005; 13: 66-73.
31. Van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB., Interleukin-6 reduces cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am J Pathol 1997; 151: 177-91.
32. Tsuchida AI, Beekhuizen M, Rutgers M, van Osch GJ, Bekkers JE, Bot AG, et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther 2012; 14: R262.
33. Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS., Interleukin-6 plays an essential role in hypoxia-inducible factor 2α-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 2011; 63: 2732-43.
34. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA., IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000; 19: 549-53.
35. Doss F, Menard J, Hauschild M, Kreutzer HJ, Mittlmeier T, Muller-Steinhardt M, et al. Elevated IL-6 levels in the synovial fluid of osteoarthritis patients stem from plasma cells. Scand J Rheumatol 2007; 36: 136-9.
36. Livshits G, Zhai G, Hart DJ, Kato BS, Wang H, Williams FM, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009; 60: 2037-45.
37. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011; 21: 10-5.
38. Maroudas A., Transport of solutes through cartilage: permeability to large molecules. J Anat 1976; 122: 335-47.
39. Van Lent PL, van den Berg WB, Schalkwijk J, van de Putte LB, van den Bersselaar L., The impact of protein size and charge on its retention in articular cartilage. J Rheumatol 1987; 14: 798-805.
40. Van Lent PL, van den Bersselaar L, Grutters GJ, van den Berg WB., Fate of antigen after intravenous and intraarticular injection into mice. Role of molecular weight and charge. J Rheumatol 1989; 16: 1295-303.